Mylan launches generic Lialda
Mylan Pharmaceuticals has received the Food and Drug Administration’s blessing for mesalamine delayed-release tablets in 1.2 gm dosage.
The product, which is a generic version of Shire's Lialda delayed-release tablets, is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis, or UC and for the maintenance of remission of UC.
Mesalamine delayed-release tablets had a market value of about $842 million for the 12 months ended Oct. 31, according to IQVIA.
The product, which is a generic version of Shire's Lialda delayed-release tablets, is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis, or UC and for the maintenance of remission of UC.
Mesalamine delayed-release tablets had a market value of about $842 million for the 12 months ended Oct. 31, according to IQVIA.